Medscape

Is Tirzepatide Easier on the Eyes Than GLP-1s?

Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients ...
MedPage Today on MSN

One GLP-1 Drug May Be Better Than Rivals for Glaucoma Risk

Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...
Ophthalmology Times

NCX 470 advances toward US, China NDA submissions for NCX 470

NCX 470 is currently licensed to Ocumension Therapeutics for China, Korea, and Southeast Asia. According to Nicox, projected ...
Medical Dialogues

Tirzepatide Linked to Lower Glaucoma Risk in Type 2 Diabetes Compared to Other Weight Loss Drugs: Study

USA: A large retrospective cohort study found that the dual GIP/GLP-1 receptor agonist tirzepatide was associated with a ...
Medical Dialogues

Patient Wealth Impacts Glaucoma Control and Follow-Up, reveals JAMA study

Researchers have found in a new study that personal wealth is strongly associated with outcomes 12–18 months after a new ...

Yineng Chen Contributes to New Study on Social and Environmental Factors Influencing Glaucoma in African Ancestry Populations

A new analysis linking clinical and census data finds individual factors, rather than neighborhood conditions, are more strongly associated ...
Agence France-Presse

ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma

ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S.
Cochrane

Factors that affect how fast glaucoma progresses

We found the following factors were important for predicting the progression of glaucoma: (1) the presence of small bleeding and poor blood flow to the retina and back of the eye, (2) abnormal cell ...